Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
Gino M Dettorre,Saoirse Dolly,Angela Loizidou,John Chester,Amanda Jackson,Uma Mukherjee,Alberto Zambelli,Juan Aguilar-Company,Mark Bower,Christopher C T Sng,Ramon Salazar,Alexia Bertuzzi,Joan Brunet,Ricard Mesia,Ailsa Sita-Lumsden,Elia Seguí,Federica Biello,Daniele Generali,Salvatore Grisanti,Pavetha Seeva,Gianpiero Rizzo,Michela Libertini,Antonio Maconi,Charlotte Moss,Beth Russell,Nadia Harbeck,Bruno Vincenzi,Rossella Bertulli,Diego Ottaviani,Raquel Liñan,Andrea Marrari,M Carmen Carmona-García,Neha Chopra,Carlo Alberto Tondini,Oriol Mirallas,Valeria Tovazzi,Vittoria Fotia,Claudia Andrea Cruz,Nadia Saoudi-Gonzalez,Eudald Felip,Ariadna Roqué,Alvin J X Lee,Tom Newsom-Davis,David García-Illescas,Roxana Reyes,Yien Ning Sophia Wong,Daniela Ferrante,Lorenza Scotti,Javier Marco-Hernández,Isabel Ruiz-Camps,Andrea Patriarca,Lorenza Rimassa,Lorenzo Chiudinelli,Michela Franchi,Armando Santoro,Aleix Prat,Alessandra Gennari,Mieke Van Hemelrijck,Josep Tabernero,Nikolaos Diamantis,David J Pinato,OnCovid study group
DOI: https://doi.org/10.1136/jitc-2020-002277
Abstract:Background: Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study. Methods: In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets. Results: We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p<0.01), recovering in survivors to pre-COVID-19 levels. Patients in poorer risk categories for each index except the PLR exhibited higher mortality rates (p<0.001) and shorter median overall survival in the training and validation sets (p<0.01). Multivariable analyses revealed the OIS to be most independently predictive of survival (validation set HR 2.48, 95% CI 1.47 to 4.20, p=0.001; adjusted concordance index score 0.611). Conclusions: Systemic inflammation is a validated prognostic domain in SARS-CoV-2-infected patients with cancer and can be used as a bedside predictor of adverse outcome. Lymphocytopenia and hypoalbuminemia as computed by the OIS are independently predictive of severe COVID-19, supporting their use for risk stratification. Reversal of the COVID-19-induced proinflammatory state is a putative therapeutic strategy in patients with cancer.